Literature DB >> 23764305

How rapidly does the excess risk of lung cancer decline following quitting smoking? A quantitative review using the negative exponential model.

John S Fry1, Peter N Lee, Barbara A Forey, Katharine J Coombs.   

Abstract

The excess lung cancer risk from smoking declines with time quit, but the shape of the decline has never been precisely modelled, or meta-analyzed. From a database of studies of at least 100 cases, we extracted 106 blocks of RRs (from 85 studies) comparing current smokers, former smokers (by time quit) and never smokers. Corresponding pseudo-numbers of cases and controls (or at-risk) formed the data for fitting the negative exponential model. We estimated the half-life (H, time in years when the excess risk becomes half that for a continuing smoker) for each block, investigated model fit, and studied heterogeneity in H. We also conducted sensitivity analyses allowing for reverse causation, either ignoring short-term quitters (S1) or considering them smokers (S2). Model fit was poor ignoring reverse causation, but much improved for both sensitivity analyses. Estimates of H were similar for all three analyses. For the best-fitting analysis (S1), H was 9.93 (95% CI 9.31-10.60), but varied by sex (females 7.92, males 10.71), and age (<50years 6.98, 70+years 12.99). Given that reverse causation is taken account of, the model adequately describes the decline in excess risk. However, estimates of H may be biased by factors including misclassification of smoking status.
Copyright © 2013 The Authors. Published by Elsevier Inc. All rights reserved.

Entities:  

Keywords:  Cessation of smoking; Lung cancer; Meta-analysis; Negative exponential model; Review; Smoking; Statistical models

Mesh:

Year:  2013        PMID: 23764305     DOI: 10.1016/j.yrtph.2013.06.001

Source DB:  PubMed          Journal:  Regul Toxicol Pharmacol        ISSN: 0273-2300            Impact factor:   3.271


  16 in total

1.  Lung Cancer Risk and Demographic Characteristics of Current 20-29 Pack-year Smokers: Implications for Screening.

Authors:  Paul F Pinsky; Barnett S Kramer
Journal:  J Natl Cancer Inst       Date:  2015-10-19       Impact factor: 13.506

2.  Proportion of Non-Small-Cell Lung Cancer Patients that Would Have Been Eligible for Lung Cancer Screening.

Authors:  Geena X Wu; Leanne Goldstein; Jae Y Kim; Dan J Raz
Journal:  Clin Lung Cancer       Date:  2016-01-14       Impact factor: 4.785

3.  5-year overall survival in patients with lung cancer eligible or ineligible for screening according to US Preventive Services Task Force criteria: a prospective, observational cohort study.

Authors:  Yung-Hung Luo; Lei Luo; Jason A Wampfler; Yi Wang; Dan Liu; Yuh-Min Chen; Alex A Adjei; David E Midthun; Ping Yang
Journal:  Lancet Oncol       Date:  2019-06-26       Impact factor: 41.316

4.  Reduction in total and major cause-specific mortality from tobacco smoking cessation: a pooled analysis of 16 population-based cohort studies in Asia.

Authors:  Jae Jeong Yang; Danxia Yu; Xiao-Ou Shu; Wanqing Wen; Shafiur Rahman; Sarah Abe; Eiko Saito; Prakash C Gupta; Jiang He; Shoichiro Tsugane; Yu-Tang Gao; Jian-Min Yuan; Woon-Puay Koh; Atsuko Sadakane; Yasutake Tomata; Ichiro Tsuji; Yumi Sugawara; Keitaro Matsuo; Yoon-Ok Ahn; Sue K Park; Yu Chen; Manami Inoue; Daehee Kang; Wei Zheng
Journal:  Int J Epidemiol       Date:  2021-02-05       Impact factor: 7.196

Review 5.  The modification of cancer risk by chemicals.

Authors:  David J Harrison; John E Doe
Journal:  Toxicol Res (Camb)       Date:  2021-07-12       Impact factor: 2.680

6.  Trends in Subpopulations at High Risk for Lung Cancer.

Authors:  Ping Yang; Yi Wang; Jason A Wampfler; Dong Xie; Shawn M Stoddard; Jun She; David E Midthun
Journal:  J Thorac Oncol       Date:  2016-02       Impact factor: 15.609

7.  Prediction of lung cancer risk based on age and smoking history.

Authors:  Jason H T Bates; Katharine L Hamlington; Garth Garrison; C Matthew Kinsey
Journal:  Comput Methods Programs Biomed       Date:  2022-01-25       Impact factor: 5.428

8.  COPD promotes migration of A549 lung cancer cells: the role of chemokine CCL21.

Authors:  Barbara Kuźnar-Kamińska; Justyna Mikuła-Pietrasik; Patrycja Sosińska; Krzysztof Książek; Halina Batura-Gabryel
Journal:  Int J Chron Obstruct Pulmon Dis       Date:  2016-05-20

9.  Anthropometry and the Risk of Lung Cancer in EPIC.

Authors:  Nikmah Utami Dewi; Hendriek C Boshuizen; Mattias Johansson; Paolo Vineis; Ellen Kampman; Annika Steffen; Anne Tjønneland; Jytte Halkjær; Kim Overvad; Gianluca Severi; Guy Fagherazzi; Marie-Christine Boutron-Ruault; Rudolf Kaaks; Kuanrong Li; Heiner Boeing; Antonia Trichopoulou; Christina Bamia; Eleni Klinaki; Rosario Tumino; Domenico Palli; Amalia Mattiello; Giovanna Tagliabue; Petra H Peeters; Roel Vermeulen; Elisabete Weiderpass; Inger Torhild Gram; José María Huerta; Antonio Agudo; María-José Sánchez; Eva Ardanaz; Miren Dorronsoro; José Ramón Quirós; Emily Sonestedt; Mikael Johansson; Kjell Grankvist; Tim Key; Kay-Tee Khaw; Nick Wareham; Amanda J Cross; Teresa Norat; Elio Riboli; Anouar Fanidi; David Muller; H Bas Bueno-de-Mesquita
Journal:  Am J Epidemiol       Date:  2016-07-01       Impact factor: 4.897

10.  Prison tobacco control policies and deaths from smoking in United States prisons: population based retrospective analysis.

Authors:  Ingrid A Binswanger; E Ann Carson; Patrick M Krueger; Shane R Mueller; John F Steiner; William J Sabol
Journal:  BMJ       Date:  2014-08-05
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.